Serum lipid profiles and schizophrenia: Effects of conventional or atypical antipsychotic drugs in Taiwan

Schizophrenia Research

Volumn 80, Issue 1, 2005, Pages 55-59

  Huang, Tiao Lai ^a   Chen, Jung Fu ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Antipsychotics; Cholesterol; Diabetes; Lipid; Schizophrenia; Triglyceride

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DISEASE SEVERITY; DRUG EFFECT; ENZYMATIC ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; TAIWAN; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TAIWAN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 27744432404     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.05.001     Document Type: Article

References (15)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed. 1994 American Psychiatric Press Washington, DC
2. P.F. Boston, S.M. Dursun, and M.A. Reveley Cholesterol and mental disorder Br. J. Psychiatry 169 1996 682 689
3. P.F. Boston, S.M. Dursun, R. Zafar, and M.A. Reveley Serum cholesterol and treatment resistance in schizophrenia Biol. Psychiatry 40 1996 542 543
4. D.E. Casey, D.G. Daniel, and A.A. Wassef Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia Neuropsychopharmacology 28 2003 182 192
5. N.G. Clark Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care 27 2004 596 601
6. T.L. Huang, and S.C. Wu Serum cholesterol levels in paranoid and nonparanoid schizophrenia associated with physical violence or suicide attempts in Taiwanese Psych. Res. 96 2000 175 178
7. T.L. Huang Serum cholesterol levels in affective disorders associated with physical violence or suicide attempts in Taiwanese Chang Gung Med. J. 24 2001 563 568
8. T.L. Huang Serum lipid profiles in major depression with clinical subtypes, suicide attempts and episodes J. Affect Disord. 86 2005 75 79
9. S.R. Kay, L.A. Opler, and J.P. Lindenmayer Reliability and validity of the positive and negative syndrome scale for schizophrenia Psychiatry Res. 23 1988 99 110
10. J.M. Meyer A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year J. Clin. Psychiatry 63 2002 425 433
11. J.M. Meyer, and C.E. Koro The effects of antipsychotic therapy on serum lipids: a comprehensive review Schizophr. Res. 70 2004 1 17
12. National Cholesterol Education Program Executive summary of the third report of the National Cholesterol Education Program (NCEP): expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
13. M.C.M. Ryan, P. Collins, and J.H. Thakore Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia Am. J. Psychiatry 160 2003 284 289
14. K. Saari, S. Lindeman, H. Koponen, J. Jokelainen, and M. Isohanni Higher serum triglyceride levels in early-onset schizophrenia Am. J. Psychiatry 161 2004 1
15. S.M. Stahl Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials J. Clin. Psychiatry 60 suppl 10 1999 31 41